US OptionsDetailed Quotes
AZN241004C80000
- 0.20
- +0.10+100.00%
15min DelayClose Oct 1 16:00 ET
0.22High0.06Low
0.09Open0.10Pre Close507 Volume3.74K Open Interest80.00Strike Price9.55KTurnover24.12%IV1.94%PremiumOct 4, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.2195Delta0.1797Gamma383.76Leverage Ratio-0.0930Theta0.0013Rho84.25Eff Leverage0.0202Vega
AstraZeneca Stock Discussion
Sign in to post a comment
Buying Esperion ESPR Now is Like Buying NVIDIA, TESLA,META,AMD,AAPL Before their share prices Rocketed 3000%+.
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks people wish they loaded up on. This isn't a Pump article. Read the facts & decide for yourself. People mostly miss out the the explosive growth curve. Esperion...
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks people wish they loaded up on. This isn't a Pump article. Read the facts & decide for yourself. People mostly miss out the the explosive growth curve. Esperion...
+15
19
3
$AstraZeneca (AZN.US)$
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
1
Buying Esperion ESPR Now is Like Buying NVIDIA, TESLA,META,AMD,AAPL Before their share prices Rocketed 3000%+.
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks you wish you had bought. Esperion is HUGELY Undervalued, company sells the ONLY statin alternative drugs with New FDA approved Primary Prevention Labels in 2024. Insurance companies are j...
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks you wish you had bought. Esperion is HUGELY Undervalued, company sells the ONLY statin alternative drugs with New FDA approved Primary Prevention Labels in 2024. Insurance companies are j...
8
2
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks you wish you had bought. Esperion is HUGELY Undervalued, company sells the ONLY statin alternative drugs with Primary Prevention Labels & Insurance companies are jumping onboard & so should YOU.
The current market-cap is below $350 million, with $200 million cash on hand, and $900 million in future milestones, with $140...
The current market-cap is below $350 million, with $200 million cash on hand, and $900 million in future milestones, with $140...
+11
13
5
The Federal Reserve on Wednesday implemented its first rate cut in over four years, reducing the benchmark rate by 50 basis points to a range of 4.75%-5%.
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
+7
73
8
Morning Movers
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...
25
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
5
1
No comment yet
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.